<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147964</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001449</org_study_id>
    <nct_id>NCT02147964</nct_id>
  </id_info>
  <brief_title>ITT-5 Mechanisms of Spermatogenesis in Man</brief_title>
  <acronym>ITT-5</acronym>
  <official_title>Mechanisms of Hormonal Control of Spermatogenesis in Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigational drug study is to determine how much male hormone,
      testosterone, is needed to maintain sperm production in the testis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a nine-month research study examining the effects on androgen treatment on sperm
      production in healthy men. There are three phase to the study, a 2-month screening phase,
      4-month treatment and 3-month follow-up. In this study, the investigators aim to define a
      quantitative relationship between intra-testicular testosterone (IT-T) and spermatogenesis in
      man. Hormone levels will be measured in a small amount of testicular fluid at the beginning
      and end of treatment and sperm concentration will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sperm concentration</measure>
    <time_frame>16 weeks</time_frame>
    <description>Difference in sperm concentration at week 16 between 4 treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IT steroid concentration</measure>
    <time_frame>16 weeks</time_frame>
    <description>It steroid concentration at week 16 between the 4 treatment groups</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gonadotropin Deficiency</condition>
  <arm_group>
    <arm_group_label>Acyline; T Gel; placebo dutasteride, placebo ketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All men will receive Acyline 300 ug/kg subcutaneous (SQ) injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
Group 1: placebo oral ketoconazole + placebo oral dutasteride for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline; T gel; Ketoconazole; placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
Group 2: oral ketoconazole 400 mg + placebo oral dutasteride for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline; Tgel; Ketoconazole; Dutasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
Group 3: Ketoconazole 400mg orally daily + Dutasteride 2.5 mg orally on day 1, followed by 0.5mg daily for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline; Tgel; HCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
Group 4: Human Chorionic gonadotropin (HCG) 60 IU injection every other day for 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone 1% Gel</intervention_name>
    <description>Testosterone 1% gel 5g daily for 4 months [all subjects]</description>
    <arm_group_label>Acyline; T Gel; placebo dutasteride, placebo ketoconazole</arm_group_label>
    <arm_group_label>Acyline; T gel; Ketoconazole; placebo</arm_group_label>
    <arm_group_label>Acyline; Tgel; Ketoconazole; Dutasteride</arm_group_label>
    <arm_group_label>Acyline; Tgel; HCG</arm_group_label>
    <other_name>T gel</other_name>
    <other_name>Testosterone gel</other_name>
    <other_name>AndroGel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>Acyline 300 ug/kg SQ injections every 2-weeks for 4 months [all subjects]</description>
    <arm_group_label>Acyline; T Gel; placebo dutasteride, placebo ketoconazole</arm_group_label>
    <arm_group_label>Acyline; T gel; Ketoconazole; placebo</arm_group_label>
    <arm_group_label>Acyline; Tgel; Ketoconazole; Dutasteride</arm_group_label>
    <arm_group_label>Acyline; Tgel; HCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months</description>
    <arm_group_label>Acyline; Tgel; Ketoconazole; Dutasteride</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>ketoconazole 400 mg PO daily for 4 months</description>
    <arm_group_label>Acyline; T gel; Ketoconazole; placebo</arm_group_label>
    <arm_group_label>Acyline; Tgel; Ketoconazole; Dutasteride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCG</intervention_name>
    <description>HCG 60 IU injection Subcutaneously, every other day for 4 months</description>
    <arm_group_label>Acyline; Tgel; HCG</arm_group_label>
    <other_name>Human chorionic gonadotropin (HCG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo dutasteride</intervention_name>
    <description>placebo oral dutasteride PO daily for 4 months</description>
    <arm_group_label>Acyline; T Gel; placebo dutasteride, placebo ketoconazole</arm_group_label>
    <arm_group_label>Acyline; T gel; Ketoconazole; placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo ketoconazole</intervention_name>
    <description>placebo ketoconazole daily for 4 months</description>
    <arm_group_label>Acyline; T Gel; placebo dutasteride, placebo ketoconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males age 18-55

          -  In general good health based on normal screening evaluation

          -  Normal serum testosterone, lutenizing hormone (LH) and follicle stimulating hormone
             (FSH)

          -  Prostate Specific Antigen (PSA) &lt; 3.0

          -  Agrees not to donate blood or participate in another research study during the study

          -  Informed consent

          -  Must be willing to use a reliable form of contraception during the study

        Exclusion Criteria:

          -  Participation in a long-term male contraceptive study within the past three months

          -  History of testosterone or anabolic steroid abuse in the past

          -  History of or current skin disorder that will interfere with testosterone gel

          -  Poor general health or significantly abnormal screening blood results

          -  History of or current testicular or prostate disease

          -  History of a bleeding disorder or need for anticoagulation

          -  History of untreated sleep apnea and/or major psychiatric problems

          -  BMI &gt; 32

          -  History of or current liver disease

          -  Chronic pain syndrome

          -  Current use of terfenidine, astemizole, cisapride, budesonide, felodipine,
             fluticasone, lovastatin, midazolam, sildenafil, or vardenafil

          -  Use of glucocorticoids or underlying adrenal insufficiency

          -  Active drug or alcohol abuse within the past year
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William J Bremner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iris Nielsen</last_name>
    <phone>206-221-5473</phone>
    <email>inielsen@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy Winter</last_name>
    <phone>206-616-0484</phone>
    <email>klwinter@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington Medical Center (Health Sciences)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iris Nielsen</last_name>
      <phone>206-221-5473</phone>
      <email>nielseni@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Winter</last_name>
      <phone>206-616-0484</phone>
      <email>klwinter@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mara Roth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Amory, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Page, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradley Anawalt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>Dedicated to basic and clinical research focused primarily on the male reproductive system</description>
  </link>
  <reference>
    <citation>Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990 Oct 20;336(8721):955-9.</citation>
    <PMID>1977002</PMID>
  </reference>
  <reference>
    <citation>Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril. 1996 Mar;65(3):626-36.</citation>
    <PMID>8774299</PMID>
  </reference>
  <reference>
    <citation>Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999 May-Jun;20(3):407-14.</citation>
    <PMID>10386821</PMID>
  </reference>
  <reference>
    <citation>Zirkin BR, Santulli R, Awoniyi CA, Ewing LL. Maintenance of advanced spermatogenic cells in the adult rat testis: quantitative relationship to testosterone concentration within the testis. Endocrinology. 1989 Jun;124(6):3043-9.</citation>
    <PMID>2498065</PMID>
  </reference>
  <reference>
    <citation>Roth MY, Lin K, Amory JK, Matsumoto AM, Anawalt BD, Snyder CN, Kalhorn TF, Bremner WJ, Page ST. Serum LH correlates highly with intratesticular steroid levels in normal men. J Androl. 2010 Mar-Apr;31(2):138-45. doi: 10.2164/jandrol.109.008391. Epub 2009 Sep 24.</citation>
    <PMID>19779211</PMID>
  </reference>
  <reference>
    <citation>Roth MY, Page ST, Lin K, Anawalt BD, Matsumoto AM, Snyder CN, Marck BT, Bremner WJ, Amory JK. Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. J Clin Endocrinol Metab. 2010 Aug;95(8):3806-13. doi: 10.1210/jc.2010-0360. Epub 2010 May 19.</citation>
    <PMID>20484472</PMID>
  </reference>
  <reference>
    <citation>Trachtenberg J, Zadra J. Steroid synthesis inhibition by ketoconazole: sites of action. Clin Invest Med. 1988 Feb;11(1):1-5.</citation>
    <PMID>2966691</PMID>
  </reference>
  <reference>
    <citation>Nashan D, Knuth UA, Weidinger G, Nieschlag E. The antimycotic drug terbinafine in contrast to ketoconazole lacks acute effects on the pituitary-testicular function of healthy men: a placebo-controlled double-blind trial. Acta Endocrinol (Copenh). 1989 May;120(5):677-81.</citation>
    <PMID>2499150</PMID>
  </reference>
  <reference>
    <citation>Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, Stevens DA. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984 Nov;144(11):2150-3.</citation>
    <PMID>6093722</PMID>
  </reference>
  <reference>
    <citation>Van Tyle JH. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343-73. Review.</citation>
    <PMID>6151171</PMID>
  </reference>
  <reference>
    <citation>Roth MY, Nya-Ngatchou JJ, Lin K, Page ST, Anawalt BD, Matsumoto AM, Marck BT, Bremner WJ, Amory JK. Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole. J Clin Endocrinol Metab. 2013 Mar;98(3):1198-206. doi: 10.1210/jc.2012-3527. Epub 2013 Jan 24.</citation>
    <PMID>23348398</PMID>
  </reference>
  <reference>
    <citation>Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, Sutton PR, Wright WW, Brown TR, Yan X, Zirkin BR, Jarow JP. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005 May;90(5):2595-602. Epub 2005 Feb 15.</citation>
    <PMID>15713727</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Mara Roth</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>intratesticular androgens</keyword>
  <keyword>testosterone</keyword>
  <keyword>dutasteride</keyword>
  <keyword>gonadotropin suppression</keyword>
  <keyword>male contraception</keyword>
  <keyword>spermatogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

